
Hepatitis A is highly endemic in developing countries. For example, in Sao Paulo, Brazil, 100% and 40.3% of lower and middle socioeconomic level children aged 2-11 years, respectively, have antibodies to hepatitis A. 90.4% of voluntary middle class adult blood donors are infected with the virus. Day care centers represent an important source of hepatitis A in several communities. Richtmann et al. investigated the immunogenicity and safety of the hepatitis A virus (HAV) strain GBM vaccine among 40 children attending a day care center in Sao Paulo. The children received three times 0.5 and 1.0 ml of the vaccine, the second and third dose one and six months after the first dose, respectively. All of the subjects had protective levels of antibodies in serum after two inoculations, with no serious adverse reactions observed. During the 8th month of follow-up, an outbreak of hepatitis A occurred in the day care center. Nine of the 27 control subjects developed either high titers of IgM class anti-HAV or acute hepatitis, but none of the vaccinated subjects developed signs or symptoms of hepatitis. This killed HAV vaccine was therefore found to be safe and effective in this area of high prevalence hepatitis A infection. Vaccination clearly benefits children in high-risk areas and should also be considered in areas of lower risk where day care centers are nonetheless important in facilitating the spread of HAV.
UNLABELLED:According to an abstract submitted by the authors to the X International Conference on AIDS, held August 7-12, 1994, in Yokohama, Japan, "OBJECTIVE:To measure the HIV-1 incidence, follow-up rates and high risk behaviors in cohorts of seronegative adults in northern Thailand.METHODS:We screened cohorts of female commercial sex workers (CSWs), male STD clinic patients, Royal Thai Army (RTA) conscripts, and discharged RTA conscripts at baseline and q3 to 6 months for HIV infection by ELISA and WB and did interviews for high risk behavior, medical history, and STD cultures.RESULTS:Of 1068 CSWs, 409 (38.3%) were HIV positive, and 396 HIV negative were enrolled in the study; follow-up at 6 months was 70.7% and 19 seroconverted, for an incidence of 12.8/100 person years. Of 1031 male STD patients, 164 (15.9%) were HIV positive, and 264 HIV negative (30.4%) were enrolled; follow-up at 6 months was 91.9% and 6 seroconverted, for an incidence of 4.92/100 person years. Of 969 RTA conscripts, 12.4% were HIV positive at baseline and 90% were followed at 6 months; 3 of 778 seroconverted, for an incidence of 0.87/100 person years. (Previous RTA cohorts have had an incidence of 3.4%/year). Among 380 men discharged from RTA, follow-up at 9 months was 81.8% and the incidence was 5.2/100 person years. Sample sizes required to show an HIV vaccine efficacy of 60%, with a power-.90, alpha-.05 varies from CSUs 644, STD patients 1456 to ex-RTA-1306.CONCLUSIONS:Several populations in northern Thailand appear to have sufficiently high HIV-1 incidence and adequate follow-up for HIV vaccine efficacy trials and other preventive intervention trials.